Evidence map›Paper›PMID 41686698›Full record

ReviewClinical and experimental immunology2026

Exosomal nanocarriers of immune fate: molecular insights into cancer immunity, pathogen defense, and emerging immunotherapies.

Kamoru A Adedokun, Aminah Bello, Gbadebo M Oyeniyi, Musa K Oladejo, Tajudeen A Adebisi

Abstract readReview
In one paragraph

Review in Clinical and experimental immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kamoru A AdedokunImmunology Department, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0001-9833-3011
Aminah BelloSchool of Biosciences, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Selangor 47500, Malaysia.ORCID 0009-0003-4918-7857
Gbadebo M OyeniyiMedical Laboratory Science Department, University of Ilorin, Ilorin, Nigeria.ORCID 0009-0007-0034-7177
Musa K OladejoZoology Department, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.ORCID 0009-0009-4949-0489
Tajudeen A AdebisiNMC Healthcare, Medical Record and Clinical Documentation Unit, Abu Dhabi 764659, UAE.ORCID 0009-0009-5600-301X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Exosomes, the nanoscale extracellular vesicles released by most cell types, are increasingly recognized as potent regulators of immune communication. This review provides a mechanistic and integrative perspective on the immunological functions of exosomes, highlighting their roles in both immune stimulation and suppression across physiological and pathological contexts. We begin by dissecting the molecular architecture of exosomes-focusing on immunologically active components such as ESCRT proteins, tetraspanins, RabGTPases, and lipid mediators-and explore how these elements contribute to exosome biogenesis and immune function. The review further examines exosomal cargo enriched in pattern recognition receptor (PRR) ligands, including damage-associated molecular patterns (DAMPs), pathogen-associated molecular patterns (PAMPs), and microRNAs, and discusses how these molecules activate toll-like receptors and other PRRs to orchestrate innate immune responses through endosomal and cytosolic signaling cascades. Special emphasis is given to MHC-mediated antigen presentation via exosomes, distinguishing classical and non-canonical pathways and their interplay with downstream immune signaling mechanisms. We present a dichotomous view of exosomes as both immunostimulatory and immunosuppressive agents, detailing their roles in T-cell cross-priming, dendritic cell maturation, tumor progression, and metastasis. Moreover, we review pathogen-driven hijacking of exosomal pathways and their implications for immune evasion. Finally, we discuss the therapeutic promise of exosomes in cancer immunotherapy and vaccine design, advocating for their strategic integration into next-generation immunomodulatory approaches.

Indexed as

ExosomesImmunotherapyNeoplasmsAnimalsAntigen PresentationHumansImmunity, InnateInnate Immunity RecognitionNanoparticlesPathogen-Associated Molecular Pattern MoleculesReceptors, Pattern RecognitionSignal TransductionPathogen-Associated Molecular Pattern MoleculesReceptors, Pattern Recognitionantigen presentationexosomesextracellular vesicle signalingimmune modulationpattern recognition receptors (PRRs)

Identifiers

PMID41686698
PMCPMC12961962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.